Related Experiment Video

Updated: Jun 18, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Statins in the prevention of heart failure after myocardial infarction

Helene Glassberg1

  • 1Department of Medicine, Section of Cardiology, Hospital of the University of Pennsylvania, 2 East Perelman Center for Advanced Medicine, 3400 Spruce Street, Philadelphia, PA 19104, USA. helene.glassberg@uphs.upenn.edu

Current Heart Failure Reports
|December 2, 2009
PubMed

Insights

Statin therapy significantly reduces cardiac events and mortality in acute coronary syndrome (ACS) and coronary artery disease patients. While some debate exists, statins likely decrease heart failure risk post-myocardial infarction (MI).

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Statin therapy is proven to reduce mortality and recurrent cardiac events in patients with acute coronary syndrome (ACS) and coronary artery disease.
  • Heart failure following myocardial infarction (MI) is linked to higher in-hospital mortality and poorer long-term outcomes.

Purpose of the Study:

  • To review existing data on the relationship between statin therapy and the incidence of heart failure after myocardial infarction (MI).
  • To discuss the potential mechanisms, safety profile, and clinical outcomes associated with statin use in the context of post-MI heart failure.

Main Methods:

  • Literature review of studies investigating statin therapy in patients with acute coronary syndrome and coronary artery disease.
  • Analysis of data concerning the incidence of heart failure post-myocardial infarction in patients receiving statin treatment.
  • Examination of proposed mechanisms, safety data, and patient outcomes related to statin use.

Main Results:

  • Statin therapy demonstrates clear benefits in reducing death and recurrent cardiac events in ACS and CAD patients.
  • Evidence suggests that statins may play a protective role in preventing heart failure development after MI and ACS, despite some existing controversy.
  • The review synthesizes data on mechanisms, safety, and outcomes, highlighting the likely favorable impact of statins on heart failure risk.

Conclusions:

  • Statin therapy is crucial for managing patients with ACS and CAD, reducing major adverse cardiac events.
  • While controversy exists, the overall evidence indicates that statins likely reduce the risk of developing heart failure after MI.
  • Further investigation into the specific mechanisms and long-term outcomes is warranted to fully elucidate the role of statins in preventing post-MI heart failure.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...